Blinatumomab Pharmacodynamics and Exposure–Response Relationships in Relapsed/Refractory Acute Lymphoblastic Leukemia

Publisher： John Wiley & Sons Inc

E-ISSN： 1552-4604|58|2|168-179

ISSN： 0091-2700

Source： JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol.58, Iss.2, 2018-02, pp. : 168-179

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 93, Iss. 3, 2018-03 ,pp. : 371-374

John Wiley & Sons Inc

Access to resources Recommend Favorite

Phase II study of methotrexate, vincristine, pegylated‐asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 2, 2015-02 ,pp. : 120-124

John Wiley & Sons Inc

Access to resources Recommend Favorite

Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia in Adult Patients

By  

Acta Haematologica, Vol. 133, Iss. 1, 2014-08 ,pp. : 89-90

Karger

Access to resources Recommend Favorite

The Combination of Fludarabine, Cytarabine and Etoposide Is an Active and Well-Tolerated Regimen in Relapsed/Refractory Acute Myeloid Leukemia

By  

Acta Haematologica, Vol. 131, Iss. 4, 2013-11 ,pp. : 202-207

Karger

Access to resources Recommend Favorite

Response to ponatinib before hematopoietic stem cell transplantation in a child with relapsed Philadelphia chromosome‐positive acute lymphoblastic leukemia

By  

PEDIATRICS INTERNATIONAL, Vol. 60, Iss. 1, 2018-01 ,pp. : 85-87

John Wiley & Sons Inc

Access to resources Recommend Favorite